Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
Forte Biosciences EPS Diluted (Quarterly) : -0.9808 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.9808 |
| March 31, 2026 | -1.241 |
| December 31, 2025 | -1.914 |
| September 30, 2025 | -0.9937 |
| June 30, 2025 | -0.9578 |
| March 31, 2025 | -1.374 |
| December 31, 2024 | -1.119 |
| September 30, 2024 | -4.542 |
| June 30, 2024 | -6.780 |
| March 31, 2024 | -4.025 |
| December 31, 2023 | -4.040 |
| September 30, 2023 | -6.573 |
| June 30, 2023 | -10.57 |
| March 31, 2023 | -8.037 |
| December 31, 2022 | -5.806 |
| September 30, 2022 | -4.491 |
| June 30, 2022 | -5.140 |
| March 31, 2022 | -4.348 |
| December 31, 2021 | -5.661 |
| September 30, 2021 | -13.61 |
| Date | Value |
|---|---|
| June 30, 2021 | -10.68 |
| March 31, 2021 | -9.062 |
| December 31, 2020 | -8.916 |
| September 30, 2020 | -11.37 |
| June 30, 2020 | -238.06 |
| March 31, 2020 | -24.22 |
| December 31, 2019 | -18.55 |
| September 30, 2019 | -8.182 |
| June 30, 2019 | -7.47 |
| March 31, 2019 | -278.05 |
| December 31, 2018 | -359.40 |
| September 30, 2018 | -7.20 |
| June 30, 2018 | -303.75 |
| March 31, 2018 | -242.64 |
| December 31, 2017 | -206.25 |
| September 30, 2017 | -187.50 |
| June 30, 2017 | -210.00 |
| March 31, 2017 | -1541.25 |
| June 30, 2016 | -1371.58 |
| March 31, 2016 | -198.75 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -23.33M |
| Total Expenses (Quarterly) | 23.33M |
| Enterprise Value | 1.378B |
| Earnings Yield | -6.66% |
| Normalized Earnings Yield | -6.663 |